HLB Acquires Non-Clinical Contract Research Organization Notus for 56.2 Billion KRW

[Asia Economy Reporter Oh Hyung-gil] HL Biopharma announced on the 27th that it will acquire Notus, a contract research organization (CRO) specializing in non-clinical trials such as animal testing.

HL Biopharma will acquire 1,405,648 shares of Notus for 56.2 billion KRW, securing an 18.37% stake and becoming the largest shareholder.

HL Biopharma stated that it decided to acquire Notus to enter new business areas and maximize synergy with its existing businesses.